Login to Your Account



Other Omontys Shoe Drops as Affymax Cuts Work Force Deep

By Randy Osborne
Staff Writer

Wednesday, March 20, 2013
Affymax Inc.'s stock-ravaging decision to let go 75 percent of its employees after the voluntary recall of Omontys (peginesatide) puts the spotlight ever more strongly on safety with regard to erythropoiesis-stimulating agents, and could bode well for Amgen Inc.'s anemia franchise.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription